EAACI Guidelines for the Use of Biologic Therapies in Severe Asthma
Targeted therapy with 1 of 5 available biologic medications may effectively manage severe asthma.
News
LATEST NEWS
Siltuximab to Be Evaluated for COVID-19 Associated ARDS in Phase 3 Trial
Siltuximab is currently marketed under the trade name Sylvant and is indicated for the treatment of multicentric Castleman’s disease.
ASAIO Recommendations for Advanced Cardiopulmonary Support for Patients With COVID-19
Recommendations by ASAIO on selection and treatment of patients with respiratory and circulatory failure associated with COVID-19 using artificial pulmonary and/or cardiac support.
Asthma Impairment and Risk Questionnaire Appropriate to Identify Asthma Control
The Asthma Impairment and Risk Questionnaire was deemed an appropriate measure to identify asthma control status in adults and adolescents that had been validated in a rigorous fashion.
US Trial Investigating Sarilumab for COVID-19 Stopped
A phase 3 trial evaluating sarilumab, an interleukin-6 antagonist, in patients with COVID-19 requiring mechanical ventilation did not meet its primary and key secondary end points.
FDA: Risk of Methanol Toxicity With Certain Hand Sanitizers
Hand sanitizers containing methanol, or wood alcohol, present a danger to individuals as the substance can be toxic when absorbed through the skin or life-threatening if ingested.
Pfizer, BioNTech’s COVID-19 Vaccine Candidate Looks Promising in Early Human Trial
Pfizer and BioNTech SE announced positive preliminary results from the phase 1/2 study evaluating the safety, tolerability, and immunogenicity of escalating doses of the vaccine candidate BNT162b1 against COVID-19.
CDC Issues Guidance on Vaccination During the COVID-19 Pandemic
Routine vaccination should not be delayed due to the COVID-19 pandemic, according to interim guidance released by the Centers for Disease Control and Prevention.
UPCOMING MEETINGS
FEBRUARY 22-25
American Academy of Allergy, Asthma and Immunology (AAAAI) 2019 Annual Meeting
San Francisco, CA
February 27-28
5th International Conference on Respiratory and Pulmonary Medicine
Paris, France
April 10-13
ELCC 2019: European Lung Cancer Conference
Geneva, Switzerland
DRUG NEWS FROM MPR
Combined Long-Acting Bronchodilator Therapy Compared With Monotherapy for COPD
Brigatinib Approved as First-Line Treatment for ALK-Positive Metastatic NSCLC
Umbilical Cord Stem Cell Therapy to Be Assessed in Severe COVID-19
FDA: Scammers Continue to Sell Unproven Products for COVID-19
Drug Shortages Reported as New Program Created to Expedite Treatments for COVID-19
FDA Approves Imfinzi for Extensive-Stage Small Cell Lung Cancer
FDA: Studies Underway to Evaluate Chloroquine for COVID-19
Pirfenidone Gets Breakthrough Therapy Status for Unclassifiable Interstitial Lung Disease
FDA: Cases of Respiratory Depression With Gabapentinoids Reported
New Cheek Swab Helps Rule Out Genetic Form of COPD
FDA Panel Votes on OTC Nicotine Mouth Spray for Smoking Cessation
Mepolizumab Approved for Younger Patients With Severe Eosinophilic Asthma
Fixed-Dose, Triple-Combination Therapy Effective in COPD Trial
Nangibotide Gets Fast Track Status for Treatment of Septic Shock
Rovalpituzumab Tesirine Program Ends After Poor Results in Lung Cancer Trial
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in News
